Low-risk persistent gestational trophoblastic disease treated with low-dose methotrexate
Author Information
Author(s): Khan F, Everard J, Ahmed S, Coleman R E, Aitken M, Hancock B W
Primary Institution: Trophoblastic Disease Centre, Academic Unit of Clinical Oncology, The University of Sheffield
Hypothesis
The study investigates the efficacy and toxicity of low-dose methotrexate in treating low-risk persistent gestational trophoblastic disease.
Conclusion
Low-dose methotrexate achieves high complete remission rates for low-risk persistent gestational trophoblastic disease with relatively low toxicity.
Supporting Evidence
- Complete remission with first-line methotrexate was achieved in 181 (72%) patients.
- In those who had first- and second-line treatment, complete remission was attained in 238 (95%).
- The overall survival of all patients was 98%, with 247 patients alive and well.
- Only 6.8% of women experienced delays during treatment.
Takeaway
This study shows that a medicine called methotrexate can help treat certain pregnancy-related diseases, and most people do well with it.
Methodology
The study involved 250 patients treated with low-dose methotrexate, monitored for hCG levels and followed up for outcomes and toxicity.
Limitations
The study may not be generalizable due to the specific patient population and treatment protocols used.
Participant Demographics
The majority of participants were women aged 39 or younger, with a median age of 27 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website